Manufacturer Communications With Payers Easier Under US FDA Guidance, But Challenges Remain
Executive Summary
Process for sharing health care economic and other information has been simplified for manufacturers, and payers are seeing more economic modeling data earlier as a result. However, there is still uncertainty as to the scope of who may communicate the information, and to whom, under the agency’s 2018 final guidance, experts said.
You may also be interested in...
US FDA Extends Payor Communications Safe Harbor To Off-Label Uses
Final guidance on drug manufacturer communications with payors adopts industry call to include exchanges about unapproved uses; they will not be considered evidence of intended use.
Industry Communications With Payors: US FDA Okays Info On Investigational Drugs
Draft guidance provides clarity on what health care economic information firms can provide to payors, formulary committees and similar entities.
Moderna’s Pediatric COVID Vaccine Packaging Spurs Confusion Concerns From CDC Panel
Discrete packaging for authorized dose in 6-11 year-olds is not yet available, so vaccination providers have to use product from a vial labeled for ‘booster doses only’ in adults. ACIP members unanimously endorse use of the mRNA vaccine in individuals ages 6-17 years but urge manufacturers to move away from relying on color to differentiate formulations.